Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Michał Dębczyński"'
Autor:
Michał Dębczyński, Damian Mojsak, Serena Tamburro, Simona Baldassari, Ilaria Musante, Rosaria Casciaro, Fabiana Ciciriello, Federico Zara, Paolo Scudieri, Giulia Gorrieri
Publikováno v:
Stem Cell Research, Vol 72, Iss , Pp 103232- (2023)
Cystic Fibrosis Transmembrane conductance Regulator (CFTR) is a chloride channel defective in cystic fibrosis (CF). Several CFTR mutations are causative of CF, among which G542X is a nonsense mutation introducing a premature stop codon which prevents
Externí odkaz:
https://doaj.org/article/4a50fda3f923421b9c320b02619a784a
Autor:
Michał Dębczyński, Giulia Gorrieri, Damian Mojsak, Floriana Guida, Federico Zara, Paolo Scudieri
Publikováno v:
Biomolecules, Vol 13, Iss 10, p 1455 (2023)
ATP12A encodes the catalytic subunit of the non-gastric proton pump, which is expressed in many epithelial tissues and mediates the secretion of protons in exchange for potassium ions. In the airways, ATP12A-dependent proton secretion contributes to
Externí odkaz:
https://doaj.org/article/e4fcc17ca85043fe808d9e56609ff549
Publikováno v:
Contemporary Oncology, Vol 25, Iss 1, Pp 53-56 (2021)
Immunotherapy is a new and very promising method of anti-cancer treatment. Unfortunately, not every patient can benefit from this treatment. The Polish drug program determines the selection of patients based on PD-L1 expression and the performanc
Externí odkaz:
https://doaj.org/article/33951a72defa418a95258e7273536311
Autor:
Michał Dębczyński, Damian Mojsak, Łukasz Minarowski, Monika Maciejewska, Paweł Lisowski, Robert M. Mróz
Publikováno v:
Advances in Medical Sciences. 68:111-120
Publikováno v:
Clinical Cancer Investigation Journal. 11:1-4
Publikováno v:
American Journal of Case Reports. 23
BACKGROUND Atezolizumab is an immune checkpoint inhibitor used as first-line treatment with carboplatin and etoposide chemotherapy for advanced small cell lung cancer. Immunochemotherapy treatment decisions can be affected by patients' physical abili
Publikováno v:
Contemporary Oncology
Contemporary Oncology, Vol 25, Iss 1, Pp 53-56 (2021)
Contemporary Oncology, Vol 25, Iss 1, Pp 53-56 (2021)
Immunotherapy is a new and very promising method of anti-cancer treatment. Unfortunately, not every patient can benefit from this treatment. The Polish drug program determines the selection of patients based on PD-L1 expression and the performanc
Autor:
Damian Mojsak, Michał Dębczyński, Beata Kuklińska, Anna Moniuszko-Malinowska, Robert Marek Mróz
Publikováno v:
American Journal of Case Reports. 23
BACKGROUND Advanced non-small cell lung cancer has poor prognosis and low survival. Immunotherapy with the use of immune checkpoint inhibitors is a relatively new method of treatment that offers a chance to significantly extend the survival and quali
Autor:
Damian Mojsak, Michał Dębczyński, Beata Kuklińska, Łukasz Minarowski, Agnieszka Kasiukiewicz, Anna Moniuszko-Malinowska, Piotr Czupryna, Robert Marek Mróz
Publikováno v:
International Journal of Environmental Research and Public Health; Volume 20; Issue 2; Pages: 1583
The COVID-19 pandemic poses a challenge to health systems worldwide. Limiting healthcare availability may delay early diagnosis and worsen the treatment effects of various diseases, including oncological diseases. We analyzed patients presenting to t
Publikováno v:
Advances in respiratory medicine. 89(3)
Chronic obstructive pulmonary disease (COPD) is a common, chronic and progressive disease that is a major public health problem worldwide. Treatment for stable COPD relies on pharmacological and non-pharmacological procedures. Education, self-managem